IP Library Granted Patent US 9,890,215
Granted Patent B2
US 9,890,215 · App. 14/158,531 · Granted Feb 13, 2018

Vista modulators for diagnosis and treatment of cancer

Inventor: Randolph J. Noelle (Plainfield, NH)
Assignees: KING'S COLLEGE LONDON; THE TRUSTEES OF DARTMOUTH COLLEGE
C07K16/2827C07K14/70532C07K16/2803A61K2039/505C07K2317/76
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,890,215
App. No.
14/158,531
Granted
Feb 13, 2018
Kind
B2
Abstract

The present disclosure relates to compositions and therapeutic methods for activating an immune response in a patient in need thereof. In a preferred embodiment, the subject methods and compositions are able to antagonize the activity of VISTA, a naturally occurring “checkpoint” protein which contributes to immune tolerance, optionally in combination with an antagonist of a second checkpoint pathway such as PD-1. For example, such methods and compositions may be suitable for preventing and treating colon cancer or another cancer. An exemplary VISTA antagonist, specifically, an anti-VISTA antibody, is demonstrated herein to activate an immune response against cancer cells in vitro and in vivo, thereby conferring protective anti-tumor immunity which decreased tumor burden. Additionally, an additive benefit was observed when a VISTA antagonist was used in combination with a second checkpoint protein antagonist, specifically, an antibody against PD-1 ligand (PD-L1).

Claims (8)

1. A method for effecting a synergistic enhancement in CD8 + T cell immunity in a subject in need thereof comprising administering a synergistic combination comprising an antagonistic anti-VISTA antibody and a PD-1 antagonist, with the proviso that the condition to which CD8 + T cell immunity is enhanced does not comprise cancer.

2. The method of claim 1 , wherein the PD-1 antagonist is an antibody.

3. The method of claim 2 , wherein the PD-1 antagonist is an anti-PD-1 or anti-PD-L1 antibody.

4. The method of claim 1 wherein the anti-VISTA antibody and the PD-1 antagonist may be in the same or different compositions.

5. The method of claim 1 , wherein the synergistic combination consists of an anti-VISTA antibody and a PD-1 antagonist.

6. The method of claim 5 , wherein the PD-1 antagonist consists of an anti-PD-1 antibody.

7. The method of claim 1 , wherein the subject has an infection and the method results in a synergistic enhancement in CTL immunity against said infection.

8. The method of claim 7 , wherein the infection is caused by a virus.

Assignments (2)
CONFIRMATORY LICENSE Recorded May 28, 2020
From: DARTMOUTH COLLEGE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 052780/0052 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 30, 2014
From: NOELLE, RANDOLPH J.
To: KING'S COLLEGE LONDON; THE TRUSTEES OF DARTMOUTH COLLEGE
Reel/Frame 032997/0930 →
Continuity (10)
Continuation In Part PCTUS2013058785 · Sep 9, 2013
Continuation In Part PCTUS2013047009 · Jun 21, 2013
Provisional Application 61663431 · Jun 22, 2012
Provisional Application 61663969 · Jun 25, 2012
Provisional Application 61735799 · Dec 11, 2012
Provisional Application 61776234 · Mar 11, 2013
Provisional Application 61807135 · Apr 1, 2013
Provisional Application 61753682 · Jan 17, 2013
Provisional Application 61698003 · Sep 7, 2012
Related Publication 20140341920A1 · Nov 20, 2014